Based on the Veru stock forecast from 5 analysts, the average analyst Veru stock price target is USD 36.50 over the next 12 months. Veru Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Veru stock forecast is Slightly Bullish, which is based on 7 positive signals and 5 negative signals. At the last closing, Veru stock price was USD 16.01. Veru stock price has changed by +3.64% over the past week, +0.71% over the past month and +115.19% over the last year.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
What we like:
High market capitalization:
Veru stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior risk adjusted returns:
Veru stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.
Superior return on equity:
Veru stock forecast has shown that the company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization:
Veru stock forecast has shown that the company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on assets:
Veru stock forecast has shown that the company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth:
Veru stock price has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio:
Veru stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What we don’t like:
The total returns for Veru stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in Veru stock.
Overpriced compared to earnings:
Veru stock price is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced compared to book value:
Veru stock price is trading high compared to its peers median on a price to book value basis.
Veru stock forecast has shown that the company had negative total cash flow in the most recent four quarters.
Negative free cash flow:
Veru stock forecast has shown that the company had negative total free cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.